0000000000687038

AUTHOR

Jacques Estève

showing 3 related works from this author

Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18…

2018

Eser, Sultan (Balikesir Author)

0301 basic medicineUniversal Health Coveragepopulation-based registriesRelative SurvivalSettore MED/42 - Igiene Generale E ApplicataCancer -- TreatmentHumans; Neoplasms; Population Surveillance; Registries; Survival Rate; Medicine (all)0302 clinical medicineNeoplasmsRegistriescancer survivaleducation.field_of_studyRelative survivalMedicine (all)EPICENEGeneral Medicine3. Good healthSurvival Ratetrend030220 oncology & carcinogenesisPopulation SurveillancePublic-Healthcancer surveillanceLiver cancersurvival ; cancer registry ; CONCORD-3CureChildhood-Cancermedicine.medical_specialtypopulation-based cancer registriesWomens CancersPopulationMedicine (all)cancer survival population-based cancer registriesSocio-culturaleUnited-StatessurvivalArticle03 medical and health sciencesBreast cancerCancer epidemiologymedicineHumansNordic-CountriesCancer -- MortalityeducationSurvival rateCancer preventionAlternative Approachbusiness.industryPublic healthCancerCancer -- Patients -- Long-term caremedicine.disease030104 developmental biologyHigh-Income Countries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessDemography
researchProduct

Neuroblastoma in Europe: differences in the pattern of disease in the UK

1998

Summary Background Neuroblastoma is a major contributor to childhood cancer mortality, but its prognosis varies with age and stage of disease, and some tumours regress spontaneously. Urinary screening programmes or clinical examination may detect the disease before symptoms appear, but the benefit of early diagnosis is uncertain. We examined the incidence, pattern, and presentation of neuroblastoma in four European countries. Methods Population-based incidence rates were derived for France, Austria, Germany, and the UK. Age, sex, and stage distribution were analysed by Mantel-Haenszel techniques and Poisson regression. The proportion of incidental diagnoses (cases without symptoms found at …

medicine.medical_specialtyPediatricseducation.field_of_studymedicine.diagnostic_testbusiness.industryPublic healthIncidence (epidemiology)Mortality ratePopulationPhysical examinationGeneral MedicineDiseaseEpidemiologymedicineOverdiagnosisbusinesseducationThe Lancet
researchProduct

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCO…

2022

BACKGROUND Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during 2000-14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0-24 years). METHODS We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0-14 years), adolescents (15-19 years), and young adults (20-24 years). We categorised leukaemia subtypes a…

AdolescentAustralia610 Medicine & healthlymphomaSettore MED/42 - Igiene Generale E ApplicatasurvivalUnited StatesEuropeLeukemia Myeloid AcuteYoung Adultchildrenpopulation-based/cancer registry360 Social problems & social servicessurvival leukemia cancer registryHematologic NeoplasmsleukaemiaPediatrics Perinatology and Child HealthDevelopmental and Educational PsychologycancerHumansRegistrieshaematological malignancy610 Medicine & healthChild360 Social problems & social services
researchProduct